Table of Contents Author Guidelines Submit a Manuscript
Journal of Cancer Epidemiology
Volume 2013, Article ID 107646, 12 pages
Methodology Report

Epidemiological Study of the Incidence of Cancers Eligible for Proton or Carbon Ions Therapy: Methodology and Results of Recruitment Estimation

1GCS ETOILE, 60 Avenue Rockefeller, 69008 Lyon, France
2Centre Régional de Lutte Contre le Cancer Léon Bérard, 28 Rue Laennec, 69008 Lyon, France
3CHU Jean Minjoz, 25030 Besançon Cedex, France
4Université Joseph Fourier, Grenoble1, BP 53-38041, Grenoble Cedex 9, France

Received 19 February 2013; Revised 16 May 2013; Accepted 22 May 2013

Academic Editor: Lynnette Ferguson

Copyright © 2013 Stéphanie Patin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Context. Hadrontherapy is an innovative form of radiotherapy using beams of protons or carbon ions able to destroy some radio-resistant tumours. Because these tumours are highly specific amongst all cancerous tumours, it is impossible to determine the incidence of these diseases from surveillance registries. Goal. To assess, within the Rhône-Alpes region, the incidence of cancers being hadrontherapy indications. Method. Prospective, multicentre continuous data collection during 1 year, by practitioners participating to multidisciplinary tumor board. Tumours are inoperable, radio resistant, at primary stage of development, or locally recurrent, with low metastatic potential. Results. Study involved 27 healthcare centres, 52 groups of specialist practitioners. The estimated incidence of cancers eligible for hadrontherapy in the Rhône-Alpes region in 2010, that is, for 34 locations in all, is of 8.5/100 000 inhabitants. Appraisal of the low potential of metastatic progression is impeded, because these are rare diseases, whose outcome is unfamiliar to investigators. Conclusion. Future epidemiological studies will need to focus on prognosis and on the metastatic progression rate of these diseases. Indeed, there are few information available on this subject in the literature that could be used to improve preventive measures, medical care, and the surveillance of these rare cancers.